基于统计的建模策略用于入口皮肤剂量估计在接受身体干预放射学的患者
Varaporn Pong Inwong1, Siritorn Buranurak2, Anucha Ahooja1
1Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
本研究引入了一种简化的统计模型,用于估计干预放射学 (IR) 程序中的患者入口皮肤剂量 (ESD). 这种用户友好的方法有助于放射科医生改进协议,并允许患者跟踪辐射暴露.
科学领域:
- 医学物理 医学物理
- 干预性放射学 干预性放射学
- 辐射剂量计 辐射剂量计
背景情况:
- 干预放射学 (IR) 提供了先进的诊断和治疗能力.
- 红血,烧伤和脱皮等放射性风险是IR手术中的担忧.
- 直接剂量测量面临挑战,包括探测器探针扰动,高成本和患者遵守.
研究的目的:
- 开发一个统计模型来估计体内IR程序的入口皮肤剂量 (ESD).
- 为了利用患者辐射剂量记录数据用于模型开发.
- 为血管和非血管IR手术创建简化,用户友好的模型.
主要方法:
- 使用患者辐射剂量记录数据开发基于统计的模型.
- 将模型分为血管和非血管IR程序的分类.
- 简化模型与传统计算方法的验证.
主要成果:
- 简化的统计模型证明了对血管和非血管IR组的患者ESD估计的充分性.
- 模型实现了ESD估计的95%置信区间.
- 开发的方法避免了复杂的参数,如反向散射因子和质量能量吸收系数.
结论:
- 易于使用的统计模型可以在机构IR程序中准确估计ESD.
- 这种方法支持放射科医生改进治疗方案和管理辐射风险.
- 患者可以在治疗后方便地监测他们收到的辐射剂量.
更多相关视频
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
相关概念视频
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Dosage Regimens: Designs and Approaches
Dosage Regimens: Partial Pharmacokinetic Parameters
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
